First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia

Journal of Diabetes

Volumn 3, Issue 3, 2011, Pages 208-216

  Tsai, Shih Tzer ^a   Pathan, Faruque ^b   Ji, Linong ^c   Yeung, Vincent Tok Fai ^d   Chadha, Manoj ^e   Suastika, Ketut ^f   Son, Hyun Shik ^g   Tan, Kevin Eng Kiat ^h   Benjasuratwong, Yupin ⁱ   Nguyen, Thy Khue ^j   Iqbal, Farrukh ^k  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b Department of Clinical Endocrinology ^*  (Bangladesh)

^c PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^d Our Lady of Maryknoll Hospital Hong Kong   (Hong Kong)

^e P D HINDUJA NATIONAL HOSPITAL   (India)

^f UDAYANA UNIVERSITY   (Indonesia)

^g Uijeongbu St Mary's Hospital   (South Korea)

^h MOUNT ELIZABETH MEDICAL CENTRE   (Singapore)

ⁱ PHRAMONGKUTKLAO HOSPITAL   (Thailand)

^j UNIVERSITY OF MEDICINE AND PHARMACY AT HO CHI MINH CITY   (Viet Nam)

^k Shaikh Zayed Postgraduate Medical Institute   (Pakistan)

more..

Author keywords

Asia; Insulin; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN;

ADULT; ARTICLE; ASIA; ASIAN; BODY WEIGHT; DIET RESTRICTION; DISEASE DURATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEMALE; FEVER; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; AGED; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SATISFACTION; PROSPECTIVE STUDIES; QUESTIONNAIRES;

EID: 80051806740     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/j.1753-0407.2011.00137.x     Document Type: Article

References (24)

1. Gregg EW, Cadwell BL, Cheng YJ et al. Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according to obesity levels in the U.S. Diabetes Care. 2004; 27: 2806-12.
2. Wang K, Li T, Xiang H. [Study on the epidemiological characteristics of diabetes mellitus and IGT in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 1998; 19: 282-5. (in Chinese).
3. Yang W, Lu J, Weng J et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010; 362: 1090-101.
4. Yoon KH, Lee JH, Kim JW et al. Epidemic obesity and Type 2 diabetes in Asia. Lancet. 2006; 368: 1681-8.
5. Chan JC, Malik V, Jia W et al. Diabetes in Asia: Epidemiology, risk factors, and pathophysiology. JAMA. 2009; 301: 2129-40.
6. McNeely MJ, Boyko EJ. Type 2 diabetes prevalence in Asian Americans: Results of a national health survey. Diabetes Care. 2004; 27: 66-9.
7. Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int. 1995; 47: 1703-20.
8. Stratton IM, Kohner EM, Aldington SJ et al. UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6years from diagnosis. Diabetologia. 2001; 44: 156-63.
9. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. A10-year follow-up of intensive glucose control in Type 2 diabetes. N Engl J Med. 2008; 359: 1577-89.
10. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-53.
11. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329: 977-86.
12. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000; 23(Suppl. 2): B21-9.
13. International Diabetes Federation. Global Guideline for Type 2 Diabetes. Available from: (accessed 4 June 2009).
14. International Diabetes Federation. Western Pacific Region Type 2 Diabetes Pratical Targets and Treatments. Available from: (accessed 4 June 2009).
15. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32: 193-203.
16. Blickle JF, Hancu N, Piletic M et al. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with Type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study. Diabetes Obes Metab. 2009; 11: 379-86.
17. Tong PC, Ko GT, So WY et al. Use of anti-diabetic drugs and glycaemic control in Type 2 diabetes: The Hong Kong Diabetes Registry. Diabetes Res Clin Pract. 2008; 82: 346-52.
18. Mohamed M. An audit on diabetes management in Asian patients treated by specialists: The Diabcare-Asia 1998 and 2003 studies. Curr Med Res Opin. 2008; 24: 507-14.
19. Chuang LM, Tsai ST, Huang BY, Tai TY. The status of diabetes control in Asia: A cross-sectional survey of 24317 patients with diabetes mellitus in 1998. Diabet Med. 2002; 19: 978-85.
20. Chan JC, Gagliardino JJ, Baik SH et al. Multifaceted determinants for achieving glycemic control: The International Diabetes Management Practice Study (IDMPS). Diabetes Care. 2009; 32: 227-33.
21. Marre M, Danchin N, Freemantle N et al. Cardiovascular Risk Evaluation in People with Type 2 Diabetes (T2D) on Insulin Therapy (CREDIT) Study: Patterns of initial prescription of insulin and associated changes in oral glucose-lowering drug (OGLD) therapy. Diabetes 2009; 58: 2014-PO (Abstract).
22. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of Type 2 diabetic patients. Diabetes Care. 2003; 26: 3080-6.
23. Fritsche A, Schweitzer MA, Haring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with Type 2 diabetes. A randomized, controlled trial. Ann Intern Med. 2003; 138: 952-9.
24. Pan CY, Sinnassamy P, Chung KD, Kim KW. Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients. Diabetes Res Clin Pract. 2007; 76: 111-8.